{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:55:54Z","timestamp":1792155354280,"version":"4.4.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Kidney disease is the fourth most common cause of non-AIDS-related mortality in people living with HIV. Combination antiretroviral therapy (cART) remains the cornerstone of treatment. However, little is known about the impact of cART on disease outcomes in patients with HIV-associated nephropathy (HIVAN) and HIV-immune complex kidney disease (HIVICK). This systematic review evaluates the impact of cART on progression to end-stage kidney disease (ESKD) and other outcomes in HIV-infected individuals. We conducted a literature search utilizing PubMed, and Cochrane database and 11 articles met inclusion criteria for analysis of which nine HIVAN studies showed decreased progression to ESKD or death for subjects when treated with cART versus those untreated. However, two studies showed no survival advantage with cART. Three HIVICK studies showed improvement in delaying ESKD in subjects on cART compared to untreated subjects. cART appeared to reduce the risk to ESKD or death in patients with both HIVAN and HIVICK.<\/jats:p>","DOI":"10.1177\/23259582221089194","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:33:15Z","timestamp":1649046795000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Antiretroviral Therapy on Kidney Disease in HIV Infected Individuals \u2013 A Qualitative Systematic Review"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6622-6297","authenticated-orcid":false,"given":"Harsha","family":"Adnani","sequence":"first","affiliation":[{"name":"Anne Arundel Medical Center, Annapolis, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Feinstein Institute for Medical Research, Northwell Health, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Khatri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Vialet","sequence":"additional","affiliation":[{"name":"North Shore University Hospital, Clinical Medical Library, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Feinstein Institute for Medical Research, Northwell Health, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cervia","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"},{"name":"North Shore University Hospital, Manhasset, New York, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"bibr1-23259582221089194","unstructured":"HIV.gov, U.S statistics. Accessed on Dec 12th, 2020, https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics."},{"key":"bibr2-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv207"},{"key":"bibr3-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1416099"},{"key":"bibr4-23259582221089194","unstructured":"National Institute of Allergy and Infectious Disease. Accessed December 19, 2020. https:\/\/www.niaid.nih.gov\/diseases-conditions\/antiretroviral-drug-development"},{"key":"bibr5-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1159\/000254381"},{"issue":"3","key":"bibr6-23259582221089194","first-page":"106","volume":"20","author":"Wyatt CM","year":"2012","journal-title":"Top Antivir Med"},{"key":"bibr7-23259582221089194","unstructured":"Juan G. Melendez Rivera, Muhammad F. Hashmi. (2021). Last visited on May 29, 2021, HIV Nephropathy, StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559134\/"},{"key":"bibr8-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.06.003"},{"key":"bibr9-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417750710"},{"key":"bibr10-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.007"},{"key":"bibr11-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv436"},{"issue":"1","key":"bibr12-23259582221089194","first-page":"13","volume":"25","author":"Wyatt CM","year":"2017","journal-title":"Top Antivir Med"},{"issue":"181","key":"bibr13-23259582221089194","first-page":"1","volume":"12","author":"Tong A","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"bibr14-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1177\/1049732310378656"},{"key":"bibr15-23259582221089194","unstructured":"Weed M. 2005. \"Meta interpretation\": a method for the interpretive synthesis of qualitative research. Forum Qualitative Sozialforschung."},{"key":"bibr16-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl337"},{"key":"bibr17-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-4-5"},{"key":"bibr18-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr376"},{"key":"bibr19-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1446-3"},{"key":"bibr20-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1086\/529385"},{"key":"bibr21-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200202000-00009"},{"key":"bibr22-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200402200-00022"},{"key":"bibr23-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165176"},{"key":"bibr24-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00865.x"},{"key":"bibr25-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.036"},{"key":"bibr26-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.002"},{"key":"bibr27-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707233170401"},{"key":"bibr28-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835521a3"},{"key":"bibr29-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"key":"bibr30-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"bibr31-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1215532"},{"key":"bibr32-23259582221089194","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Accessed July 6, 2021. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines. The U.S. Department of Health and Human Services clinical guidelines for antiretroviral therapy for adults living with HIV."},{"issue":"3","key":"bibr33-23259582221089194","first-page":"24S","volume":"33","author":"Cutrell J","year":"2016","journal-title":"Fed Pract"},{"issue":"1","key":"bibr34-23259582221089194","first-page":"44","volume":"40","author":"Truong WR","year":"2015","journal-title":"Pharm Therapeut"},{"key":"bibr35-23259582221089194","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v19i1.817"},{"key":"bibr36-23259582221089194","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v21i1.1115"},{"key":"bibr37-23259582221089194","unstructured":"European AIDS Clinical Society, guidelines version 10.1, October 2020. Accessed May 30, 2021. http:\/\/www.eacsociety.org\/Guidelines.aspx"},{"key":"bibr38-23259582221089194","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0024-z"},{"key":"bibr39-23259582221089194","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081254"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582221089194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582221089194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582221089194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:06Z","timestamp":1777503006000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582221089194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"alternative-id":["10.1177\/23259582221089194"],"URL":"https:\/\/doi.org\/10.1177\/23259582221089194","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"23259582221089194"}}